1
|
Abdraboh ME, Daw DS, AbouEl-ezz AM, El-Kholy WM. Impact of the phytochemicals cocktail "breast safeguard" in regulating the interplay between redox signalling and murine adenocarcinoma cell proliferation, survival and angiogenesis. Heliyon 2021; 7:e07562. [PMID: 34355084 PMCID: PMC8322271 DOI: 10.1016/j.heliyon.2021.e07562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 05/29/2021] [Accepted: 07/08/2021] [Indexed: 02/07/2023] Open
Abstract
Phytochemicals are natural plant extracts with a potent antioxidant, anti-inflammatory and anticancer characteristics by acting as a cell signalling modulator. This study aims to evaluate the effect of a commercial cocktail of phytochemicals "Breast safeguard" (BSG) in upregulating the expression of antioxidant enzymes to counteract signalling pathways that promote Ehrlich cells progression. The potent antioxidant activity and total phenolics and flavonoids contents of BSG was chemically validated, BSG treated mice showed a significant reduction at the tumor size, along with significant reduction in the expression of prognostic markers CEA and TNFα and induction of cell cycle arrest at G1/S phase as well as downregulation of Ki67. BSG supplementation significantly diminished H2O2, NO, MDA levels and upregulated the expression of SOD, CAT, GPx and GSH antioxidant enzymes in plasma and tumor tissues. BSG treatment markedly activated P53/Bax/Bcl2/c-caspase 3 signalling for cell apoptosis and attenuated the expression of antiapoptotic survivin protein. Meanwhile, BSG significantly diminished the expression of VEGF as an indication of angiogenesis inhibition. In conclusion, BSG exerted a significant upregulation of antioxidant enzymes which may be involved in upregulating P53/Bax/c-caspase 3 expression and attenuation of cell proliferation and angiogenesis.
Collapse
Affiliation(s)
| | - Daw S. Daw
- Department of Zoology, Faculty of Science, Mansoura University, Egypt
| | - Ali M. AbouEl-ezz
- Department of Zoology, Faculty of Science, Mansoura University, Egypt
| | - Wafaa M. El-Kholy
- Department of Zoology, Faculty of Science, Mansoura University, Egypt
| |
Collapse
|
2
|
Lien C, Huang S, Hua Chen Y, Cheng W. Evidenced-based practice of decision-making process in oncofertility care among registered nurses: A qualitative study. Nurs Open 2021; 8:799-807. [PMID: 33570287 PMCID: PMC7877121 DOI: 10.1002/nop2.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 09/28/2020] [Accepted: 10/27/2020] [Indexed: 11/23/2022] Open
Abstract
AIM The purpose of our study was to construct the context of the nursing action/role in oncofertility care. DESIGN Qualitative research. METHODS We applied grounded theory to guide the qualitative study. Data were collected through in-depth interviews with 12 nurses in Taipei. The data were collected from August 2018 to February 2019. RESULTS The core theme that described the role of nurses' decision-making in oncofertility care focused on understanding oncofertility from the self to the other. Care roles or actions in oncofertility that involved the process of psychological cognition were divided into four dimensions: perceiving the patient's changes and needs, triggering the self's emotions, empathizing with patient's situations and introspective care roles. Nurses who had experienced the phase of empathizing with the patient's situations developed more diverse roles and had positive actions toward oncofertility care. Based on the psychological changes for oncofertility decision-making process, implementing contextual training in oncofertility could help nurses create more positive actions in oncofertility care.
Collapse
Affiliation(s)
| | | | - Yi Hua Chen
- Department of NursingMackay Medical CollegeNew Taipei CityTaiwan
| | - Wen‐Ting Cheng
- Department of NursingMacKay Memorial HospitalTaipeiTaiwan
| |
Collapse
|
3
|
Ostroot MK, Heslin K, Kram JJF, Tjoe JA, Dorton B. Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age. Eur J Obstet Gynecol Reprod Biol 2020; 258:174-178. [PMID: 33444811 DOI: 10.1016/j.ejogrb.2020.12.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Accepted: 12/20/2020] [Indexed: 10/22/2022]
Abstract
OBJECTIVE To assess the risk of recurrence with hormonal contraceptive use in breast cancer survivors of reproductive age. STUDY DESIGN In this retrospective study, women ages 18-51 years who were diagnosed with primary stage 0-3 breast cancer between 2006-2016 and subsequently entered remission were included. Patients with missing information within the cancer registry or electronic medical record and those with a history of hysterectomy and/or sterilization procedure prior to diagnosis were excluded. Hormonal contraception use was defined as being prescribed an oral contraceptive pill (OCP), patch, vaginal ring, medroxyprogesterone injection, etonogestrel implant, or levonorgestrel-releasing intrauterine device (IUD). Women were separated into two groups, hormonal contraceptive users and non-users. Basic descriptive and inferential statistics were used to compare groups as appropriate. The primary outcome reviewed was local or distant breast cancer recurrence. Secondary outcomes included all-cause mortality and pregnancy. RESULTS Following exclusions, 1370 women remained in the cohort. Ninety-seven women (7.08 %) received a prescription for a form of hormonal contraception. When comparing groups, hormonal contraceptive users were more likely to be between 18-40 years of age (46.39 % vs. 17.99 % non-users;P < 0.01) and never smokers (68.04 % vs. 38.57 % non-users; P < 0.01). Patients did not differ between groups based on any other demographic or cancer-related characteristic, including tumor hormone receptor expression. Overall, 92 patients (6.72 %) experienced local or distant recurrence during the study period. Recurrence did not differ between groups (6.19 % users vs. 6.76 % non-users; P = 0.83). All-cause mortality and pregnancy rates also did not differ between hormonal contraceptive users and non-users. CONCLUSION The study shows no increased risk of recurrence associated with hormonal contraceptive use after breast cancer diagnosis and remission.
Collapse
Affiliation(s)
- Molly K Ostroot
- Department of Obstetrics and Gynecology, Advocate Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, United States.
| | - Kayla Heslin
- Advocate Aurora Research Institute, Advocate Aurora Health Care, Milwaukee, WI, United States; Aurora University of Wiscons in Medical Group and Center for Urban Population Health, Advocate Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, United States
| | - Jessica J F Kram
- Aurora University of Wiscons in Medical Group and Center for Urban Population Health, Advocate Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, United States
| | - Judy A Tjoe
- Advocate Aurora Research Institute, Advocate Aurora Health Care, Milwaukee, WI, United States; Department of Surgical Breast Oncology, Advocate Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, United States; Translational Oncology Research Quest for Understanding and Exploration (TORQUE), Advocate Aurora Health Care, Milwaukee, WI, United States
| | - Benjamin Dorton
- Department of Obstetrics and Gynecology, Advocate Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, United States
| |
Collapse
|
4
|
Serfaty D. Update on the contraceptive contraindications. J Gynecol Obstet Hum Reprod 2019; 48:297-307. [DOI: 10.1016/j.jogoh.2019.02.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 01/25/2019] [Accepted: 02/19/2019] [Indexed: 10/27/2022]
|
5
|
Rubinsak LA, Christianson MS, Akers A, Carter J, Kaunitz AM, Temkin SM. Reproductive health care across the lifecourse of the female cancer patient. Support Care Cancer 2018; 27:23-32. [DOI: 10.1007/s00520-018-4360-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 07/17/2018] [Indexed: 10/28/2022]
|
6
|
|
7
|
Decision-Making Process Regarding Fertility Among Reproductive-Age Women With Cancer in Taiwan. Cancer Nurs 2017; 40:394-402. [PMID: 27753649 DOI: 10.1097/ncc.0000000000000439] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
BACKGROUND Previous studies indicate that women with cancer experience infertility after cancer-related treatment. With the rapid progress in fertility science, women face diverse and uncertain choices regarding pregnancy. OBJECTIVE The aim of this study is to understand the decision-making process regarding fertility choices among reproductive-age women with cancer in Taiwan. METHODS Grounded theory methodology guided data collection using in-depth interviews with 18 women diagnosed and treated for cancer. Verbatim transcriptions were analyzed using constant comparative analysis and open, axial, and selective coding. RESULTS The core category that describes the decision-making process regarding fertility among reproductive-age women with cancer is "searching for balance in life and creating value in life." The decision process was divided into 3 phases: needing to have children before treatment, struggling with self-living during cancer treatment, and returning to life after treatment. The style of cancer participants' decision making in pregnancy was divided into 3 patterns: action taking, hesitation, and persistence. CONCLUSIONS Decision making regarding fertility among women with cancer was affected by the need for children before treatment and their experience during treatment. IMPLICATIONS FOR PRACTICE Health providers should be aware of and understand the needs of women with cancer to balance their need for children with their perception of their cancer prognosis and its effects on fertility, and help them with pregnancy planning if desired.
Collapse
|
8
|
Hsieh PL, Huang SM, Chien LY, Lee CF, Hsiung Y, Tai CJ. Risk-benefit perception of pregnancy among breast cancer survivors. Eur J Cancer Care (Engl) 2017; 27:e12696. [DOI: 10.1111/ecc.12696] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/18/2017] [Indexed: 01/10/2023]
Affiliation(s)
- P.-L. Hsieh
- Department of Nursing; Mackay Medical College; New Taipei City Taiwan
| | - S.-M. Huang
- Department of Nursing; Mackay Medical College; New Taipei City Taiwan
| | - L.-Y. Chien
- Institute of Community Health care; National Yang-Ming University; Taipei Taiwan
| | - C.-F. Lee
- Department of Nursing; Mackay Medical College; New Taipei City Taiwan
| | - Y. Hsiung
- Department of Nursing; Mackay Medical College; New Taipei City Taiwan
| | - C.-J. Tai
- Department of Traditional Chinese Medicine; Taipei Medical University Hospital; Taipei Taiwan
- Department of OB/GYN; School of Medicine; College of Medicine; Taipei Medical University; Taipei Taiwan
| |
Collapse
|
9
|
Contraception counseling for young breast cancer patients: A practical needs assessment and a survey among medical oncologists. Breast 2016; 30:217-221. [DOI: 10.1016/j.breast.2015.10.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Revised: 09/16/2015] [Accepted: 10/01/2015] [Indexed: 12/18/2022] Open
|
10
|
Caring for breast cancer survivors in primary care. JAAPA 2016; 29:16-22. [DOI: 10.1097/01.jaa.0000496950.95334.86] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Faubion SS, Loprinzi CL, Ruddy KJ. Management of Hormone Deprivation Symptoms After Cancer. Mayo Clin Proc 2016; 91:1133-46. [PMID: 27492917 DOI: 10.1016/j.mayocp.2016.04.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 03/03/2016] [Accepted: 04/05/2016] [Indexed: 02/08/2023]
Abstract
Cancer survivors often experience symptoms related to hormone deprivation, including vasomotor symptoms, genitourinary symptoms, and sexual health concerns. These symptoms can occur due to natural menopause in midlife women, or they can be brought on by oncologic therapies in younger women or men. We searched PubMed for English-language studies from January 1990 through January 2016 to identify relevant articles on the management of hormone deprivation symptoms, including vasomotor, genitourinary, and sexual symptoms in patients with cancer. The search terms used included hormone deprivation, vasomotor symptoms, hot flash, vaginal dryness, sexual dysfunction, and breast cancer. This manuscript provides a comprehensive description of data supporting the treatment of symptoms associated with hormone deprivation.
Collapse
Affiliation(s)
- Stephanie S Faubion
- Women's Health Clinic, Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.
| | - Charles L Loprinzi
- Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN
| | - Kathryn J Ruddy
- Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN
| |
Collapse
|
12
|
|
13
|
Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F. Breast cancer under age 40: a different approach. Curr Treat Options Oncol 2015; 16:16. [PMID: 25796377 DOI: 10.1007/s11864-015-0334-8] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Breast cancer (BC) under age 40 is a complex disease to manage due to the additionally fertility-related factors to be taken in consideration. More than 90% of young patients with BC are symptomatic. Women<40 years are more likely to develop BC with worse clinicopathological features and more aggressive subtype. This has been frequently associated with inferior outcomes. Recently, the prognostic significance of age<40 has been shown to differ according to the BC subtype, being associated with worst recurrence-free survival (RFS) and overall survival (OS) for luminal BC. The biology of BC<40 has also been explored through analysis of large genomic data set, and specific pathways overexpressed in these tumors have been identified which can lead to the development of targeted therapy in the future. A multidisciplinary tumor board should determine the optimal locoregional and systemic management strategies for every individual patient with BC before the start of any therapy including surgery. This applies to both early (early breast cancer (EBC)) and advanced (advanced breast cancer (ABC)) disease, before the start of any therapy. Mastectomy even in young patients confers no overall survival advantage when compared to breast-conserving treatment (BCT), followed by radiotherapy. Regarding axillary approach, indications are identical to other age groups. Young age is one of the most important risk factors for local recurrence after both breast-conserving surgery (BCS) and mastectomy, associated with a higher risk of distant metastasis and death. Radiation after BCS reduces local recurrence from 19.5 to 10.2% in BC patients 40 years and younger. The indications for and the choice of systemic treatment for invasive BC (both early and advanced disease) should not be based on age alone but driven by the biological characteristics of the individual tumor (including hormone receptor status, human epidermal growth factor receptor 2 (HER-2) status, grade, and proliferative activity), disease stage, and patient's comorbidities. Recommendations regarding the use of genomic profiles such as MammaPrint, Oncotype Dx, and Genomic grade index in young women are similar to the general BC population. Especially in the metastatic setting, patient preferences should always be taken into account, as the disease is incurable. The best strategy for these patients is the inclusion into well-designed, independent, prospective randomized clinical trials. Metastatic disease should always be biopsied whenever feasible for histological confirmation and reassessment of biology. Endocrine therapy is the preferred option for hormone receptor-positive disease (HR+ve), even in presence of visceral metastases, unless there is concern or proof of endocrine resistance or there is a need for rapid disease response and/or symptom control. Recommendations for chemotherapy (CT) should not differ from those for older patients with the same characteristics of the metastatic disease and its extent. Young age by itself should not be an indication to prescribe more intensive and combination CT regimens over the sequential use of monotherapy. Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) represent an important group of promising drugs in managing patients with breast cancer susceptibility gene (BRCA)-1- or BRCA-2-associated BC. Specific age-related side effects of systemic treatment (e.g., menopausal symptoms, change in body image, bone morbidity, cognitive function impairment, fertility damage, sexual dysfunction) and the social impact of diagnosis and treatment (job discrimination, taking care for children) should also be carefully addressed when planning systemic long-lasting therapy, such as endocrine therapy. Survivorship concerns for young women are different compared to older women, including issues of fertility, preservation, and pregnancy.
Collapse
Affiliation(s)
- D Ribnikar
- Medical Oncology Department, Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | | | | | | | | | | | | | | | | |
Collapse
|